Trial Profile
Safety of Abatacept in patients with interstitial lung disease and common variable immunodeficiency (CVID) and related disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Common variable immunodeficiency; Interstitial lung diseases
- Focus Adverse reactions
- Acronyms SAIL
- 14 Dec 2018 Status changed from recruiting to completed.
- 02 Dec 2016 Status changed from not yet recruiting to recruiting
- 24 Jun 2016 New trial record